Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? - Wikidata - awgldk - TriplyDB

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

http://www.wikidata.org/entity/Q36610851

about

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.Basic principles and technologies for deciphering the genetic map of cancer.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.PharmGKB summary: gemcitabine pathway SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study Clinical pharmacology and pharmacogenetics of gemcitabine.Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.Novel strategy with gemcitabine for advanced pancreatic cancer.Antimetabolite Treatment for Pancreatic Cancer.Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography Gemcitabine in the treatment of metastatic pancreatic cancer.Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.Pancreatic adenocarcinoma: new strategies for success Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer.SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Pharmacogenomics in bladder cancer.Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

P2860

Q26752368-40B7300F-3537-408D-9C98-7D86A9705513 Q29616287-2879C43D-0DF9-4798-BA69-205A6830FC6F Q30238470-C601AA88-9D6D-4CB8-A0E4-3EB463CF9406 Q33385281-BC265994-2ED4-4190-BE41-61CB207D40F8 Q33395417-33C7577D-5D16-44E9-8D0D-23A059972B78 Q33575608-AE9A670E-197D-469D-83D0-444768813BC8 Q33591937-AB708DCD-B3BC-4173-B6A9-3DC0DAE92FAB Q33670961-135F153F-92C0-44E5-B425-227424FE5D7F Q33889319-B3ED9402-6947-4B7D-9A2F-7F632CDF267E Q34074628-F3EC916C-7581-481E-8C1D-53A396372ACC Q34205171-BDEDEDF5-3DC8-4BDF-91BD-117420A35CB8 Q34254837-13C43327-6786-4DBC-8740-8E7D8416C618 Q34395614-BC69565B-4F19-4207-8BB5-313A54A4511B Q34435450-98087C7D-28BE-4968-8568-3BED879267E6 Q34528361-F423FD6B-659B-4E2B-B746-DBCE5D99CCA9 Q34985979-5297893D-9879-4C88-8707-6294B670F16C Q35130652-5CC51022-CA95-4598-B203-9B095FDEEB1A Q35432223-00EF11AB-DE91-40B4-9AB5-74052297F886 Q35826334-0B2639AC-6A12-4303-B6A5-AD435A1B55A2 Q35830711-A6EFD1FD-3569-4C93-8CAB-F4BC311F1108 Q35870211-0A2E2310-73F3-433B-8114-46CE726671EC Q35909171-EEF9270D-A6CF-4F94-B113-D8810E31E09F Q36201693-E8481A86-9E9A-434A-8851-C754AE019A37 Q36302124-B3FED979-1B66-4703-B01B-00CB236C5EE4 Q36373429-C7429BF6-2370-4646-B49D-3B6023FB3F68 Q36429978-7F4CC759-A987-4E45-A1E4-D961632D9E79 Q37066064-E8AEF998-F14F-41FE-A327-EA8A26982943 Q37085729-B4A7EB15-7B06-40CD-A7B7-F15925E7DD85 Q37134412-CD89C98D-F187-4B0C-9042-1F605163142B Q37141957-D28C5076-A086-4DD5-888F-3A93BE4C3A21 Q37198628-95BCF3CF-6C8C-4543-9B8B-962B997E21AD Q37440160-BC1A0CFF-4E43-4982-B348-6817835E1069 Q37507420-C8A3368F-01D3-4732-A17E-A70987068632 Q37523551-26488CED-574D-4AA4-A5EB-0325782BF933 Q37593002-1DB0FF74-FF70-47E9-8112-25BBC106A75A Q37876401-0546A289-D277-4034-9B1F-CB3790F755C5 Q37955222-B3E8A8FA-90AF-410A-B8CE-980EF35B9D26 Q38058785-49B7481F-6BDA-468C-9CBE-5F8AC78B3899 Q38461595-CAB46FBD-50DA-41A6-812D-5E028E0785A6 Q38835169-D464226D-063C-4846-8AFF-A968EAE9473B

P2860

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

http://www.wikidata.org/entity/Q36610851

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@ast

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@en

type

label

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@ast

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@en

prefLabel

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@ast

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@en

P1433

Q36610851-F43FA7A8-5297-4B35-8647-87A118BBCC09

P1476

Q36610851-6B32B1F1-402E-41BE-A78D-5FBDC0C12C49

P2093

Q36610851-30BB29E5-43F4-4442-BB32-62E5027A0972

Q36610851-6E7B64DF-C6F5-46D1-AD83-1C2E31EFA0C3

Q36610851-8994C561-C7F1-4F6C-B276-6D8A5099ECAA

P2860

Q36610851-03A43F0A-C9B5-4320-8F86-D67942BE466E

Q36610851-0B350169-61DD-47DA-B4A8-FFB25AFB7330

Q36610851-0C68C454-9E4F-42AD-A07E-C859CA2D8EBA

Q36610851-15B935B6-9FDC-4671-977A-1BDC08210B64

Q36610851-17DF9349-0D14-458C-B799-FF648EC65909

Q36610851-329B3FAA-749C-466E-AA3A-71E975D914F8

Q36610851-3684A6AF-4CB4-4EE2-85F6-E5975DFB2FD9

Q36610851-36DC3615-4BCA-4B9A-BC72-73D67A4E8511

Q36610851-3EBDF157-429C-4466-B122-D50075F0C53E

Q36610851-43075A63-A39C-4668-A01F-152D50584203

P2888

Q36610851-3102EC80-B16C-427F-AC1D-67603C1F00B9

P304

Q36610851-761516A3-7438-40F8-B2A6-0C4E673D222F

P31

Q36610851-BBAA1AFF-2D71-4D32-9FE6-A73AC6E921BC

Q36610851-BC8F51F4-1A37-418B-8EF3-16AAF6426565

P356

Q36610851-D5D12A59-E847-4621-BE22-F500D9348BF1

P407

Q36610851-8AE8F109-5D3F-492F-B242-4886BA87B97C

P433

Q36610851-1E0AC66F-BF78-4117-ABF4-9E6577BB8655

P478

Q36610851-45C09EEA-6573-4075-B1CE-6828D5E2D4F7

P577

Q36610851-2A6A79B6-A0CB-4A63-A174-327F458EDB63

Q36610851-87347D96-CFD2-4407-9320-2921523B7D43

P5875

Q36610851-C079AF83-AD4E-4184-A8AA-F997DD330968

P698

Q36610851-67661B5D-CB78-43A2-B4D3-4AB676F695B1

P921

Q36610851-365F936E-6C74-4985-AAA9-FD9113594FA9

Q36610851-E46A57F8-EBC1-400B-BBCF-F9D7F27B968C

Q36610851-F2C1535A-4A40-4FEC-9CD4-E28BC58C2B0C

P932

Q36610851-E5DCBB6C-E7CE-4C9A-9BB5-76CB286F862D

P356

P1433

British Journal of Cancer

P1476

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

@en

P2093

H Ueno

http://www.w3.org/2001/XMLSchema#string

K Kiyosawa

http://www.w3.org/2001/XMLSchema#string

N Kaniwa

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.

Cellular pharmacology of gemcitabine.

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

P2888

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603860

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2007-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6241153

http://www.w3.org/2001/XMLSchema#string

P698

17595663

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

mechanism of action

genetic variation

P932

2360307

http://www.w3.org/2001/XMLSchema#string